Hello Heart collects $12M for digital chronic disease management

The startup is looking to buff up its sales teams with the Series B funding.
By Dave Muoio
Share

Hello Heart, maker of a digital chronic disease health program for employees, has raised $12 million in Series B funding. The round was led by Khosla Ventures, with additional support from previous backers BlueRun Ventures, Maven Ventures and Resolute Ventures.

WHAT THEY DO

Hello Heart’s bread and butter is its app-driven platform for hypertension, blood pressure and general cardiovascular health management. Marketed toward large employers, the tool helps users track their condition over time, incorporates a Bluetooth-connected blood pressure monitor, automatically imports users’ clinical lab results and promotes medication adherence.

The company also branched out into diabetes management in 2018, adding blood sugar tracking tools alongside new personalized prompts designed to drive healthy behavior change.

“A lot of our patients that have hypertension also have diabetes, so we want to manage all of their health in one place. Initial results are very promising,” CEO Maayan Cohen told MobiHealthNews at the time. “For our clients that [have] already seen a great success with using Hello Heart for their population, it makes sense for them to enroll the second [most prevalent] condition using the same module as well.”

WHAT IT’S FOR

Cohen said in today’s statement that the company has plans in place to expand, and is currently “scaling up our sales team in the employers and health plan space.”

MARKET SNAPSHOT

Digital chronic disease management enjoyed some level of market validation last week when Livongo debuted on the public market well above its initial asking price. Meanwhile Omada Health brought in $73 million for its own chronic disease management platform at the end of June, which it said will fuel the growth of its program.

ON THE RECORD

“Every consumer should be the CEO of their own health. Hello Heart is one of the only digital health solutions in hypertension that we have seen that has the potential to move the needle on population health and in delivering long term clinical impact,” Vinod Khosla, managing partner of Khosla Ventures, said in a statement. “We are very excited to be a part of their journey.”